Journal
EPILEPSY & BEHAVIOR CASE REPORTS
Volume 6, Issue -, Pages 28-29Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ebcr.2016.05.001
Keywords
Perampanel; Myoclonus; Lance-Adams syndrome; Efficacy
Categories
Ask authors/readers for more resources
Perampanel (PER) is the first-in-class selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic-clonic seizures. A positive effect was reported in some patients with epileptic myoclonic jerks in idiopathic generalized epilepsy and in progressive myoclonic epilepsy. We treated a male patient with posthypoxic nonepileptic myoclonus (Lance-Adams syndrome) with add-on PER and achieved an almost complete cessation of jerks. This effect was reproducible and, therefore, we suggest that it might be worth trying PER in comparable cases. (C) 2016 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available